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BRAFV600ESummary Gangliogliomas are uncommon glioneuronal tumors, which usually arise in the cerebral
hemispheres and occasionally in the brain stem. Gangliogliomas occurring in the spinal cord are
extremely rare. In this study, we analyzed the clinical, histopathologic, and molecular features of 25
spinal gangliogliomas. The cases included in our series affected mostly children and young adults
(15 males and 10 females; mean age, 20 years; median age, 14 years; age range, 1-72 years) and were
predominantly localized in the cervical and thoracic spine. From the clinical point of view (detailed
follow-up available for 9 pediatric cases; mean follow-up: 2 years 10 months; range, 3 months to 5 years
10 months), most patients showed stable disease after subtotal resection. Radiotherapy was rarely used
as adjuvant treatment. Histologically, gangliogliomas (WHO grade I) (21 cases) showed features largely
similar to their supratentorial counterparts. Anaplastic gangliogliomas (World Health Organization
grade III) (4 cases) showed features of anaplasia (including high cellularity and increased mitotic and
proliferation activity). From a molecular point of view, only 2 tumors (2/19, 11%) harbored a
BRAFV600E mutation. In conclusion, although spinal gangliogliomas display histologic and clinical
features similar to their supratentorial counterparts, they show a relatively low frequency of BRAFV600E
mutations, alteration otherwise common in hemispheric and brain stem gangliogliomas.
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Gangliogliomas (GGs) are uncommon neuroepithelial
tumors, which are composed of glial cells as well as
dysplastic neurons [1]. They account for 2% of the central
nervous system (CNS) neoplasms [1]. Although they may
occur throughout the CNS, they are typically hemispheric
108 M. Gessi et al.with a predilection for the temporal lobes, where they
represent one of the most common epilepsy-associated
tumors [1]. GGs are rarely diagnosed in the spinal cord
[2-5], accounting for less than 10% of all intramedullary
neoplasms in some series [6]. Although several cases have
been described as case reports, no large cohort of spinal GG
was analyzed in detail, focusing on their neuropathological
and molecular features.
In this study, we investigated the clinical, histopathologic,
and molecular features of 25 spinal GGs.2. Materials and methods
2.1. Patients and tissues
Twenty-five formalin-fixed, paraffin-embedded tissue
specimens of spinal GG were retrieved from the archive of
the Institute of Neuropathology, University of Bonn medical
Center, and the DGNN German Brain Tumor Reference
Center, Bonn, Germany (between 2000 and 2015). Detailed
follow-up (FU) information was available for 9 pediatric
patients enrolled in theHIT-LGG 1996 protocol of the German
Society of Pediatric Oncology and Hematology (GPOH).
2.2. Immunohistochemistry
Immunohistochemistry was performed on a semiauto-
mated immunohistochemistry stainer (Tecan, Crailsheim,
Germany) or a Ventana Benchmark XT Immunostainer
(Roche Ventana, Darmstadt, Germany) with antibodies
against glial fibrillary acidic protein (dilution 1:1000;
Dako, Hamburg, Germany), microtubule-associated protein
2 (MAP2C) (1:20000; Sigma, St Louis, MO), p53 protein
(1:150; Dako), BRAFV600E protein (clone VE1, 1:200;
Spring Bioscience, Pleasanton, CA), S-100 protein (1:2000;
Dako), CD34 (1:1000; Dako), synaptophysin (1:200; Dako),
NeuN (1:100; Dako), chromogranin A (1:1000; Dako),
neurofilament (1:1000; Dako), H3.3K27M (1:500; Millipore,
Temecula, CA) and trimethylated H3.3 (1:200; Cell Signaling,
Danvers, MA), and Ki-67 (Mib-1, 1:500; Dako). The
proliferation index was expressed as percentage of stained cells.
2.3. DNA extraction, BRAFV600E mutation analysis,
and KIAA1549-BRAF fusion status analysis
Hematoxylin and eosin–stained sections of each case were
reviewed carefully before they were selected for DNA
extraction. All samples selected contained at least 80% of
viable tumor. DNA from 13 cases was extracted using the
QIAamp DNAMini Tissue Kit (Qiagen, Düsseldorf, Germany)
according to the manufacturer's instructions. We screened the
hotspot codon 600 (exon 15) of the BRAF gene for mutations
using a pyrosequencing assay as reported in detail elsewhere [7].
As a positive control for the screening, DNA from a BRAFV600Emutated melanoma brain metastasis was used. The
KIAA1549-BRAF fusion was studied using a multiplex
ligation-dependent probe amplification (MLPA)–based ap-
proach [8]. Twelve caseswith availableDNAwere investigated.
The P370 MLPA kit (MRC Holland, Amsterdam, The
Netherlands) was used. This kit contains multiple specific
hybridization probes for both KIAA1549 and BRAF genes,
within and outside the parts of genes that undergo fusion. The
formation of the fusion is associated to the generation of an extra
copy that can be detected by a quantitative assessment of regions
included and not included in the fusion. The MLPA analysis of
these cases was performed along with 3 positive controls
(pilocytic astrocytomas with known BRAF fusions) and 3
negative controls (normal cerebellar tissue), following the
manufacturer's instructions. The results were analyzed using the
Coffalyser.net software (MRC Holland).3. Results
3.1. Clinical and neuroradiological features
The series included tumors from 25 patients (15 males
and 10 females), comprising 7 adults and 18 children (mean
age, 20.5 years; median age, 14 years, age range, 1-72 years).
Two tumors were localized in the upper cervical spine
extending into the medulla oblongata, 12 were cervical (6 of
these affected also the thoracic spine), 5 were exclusively
thoracic, and 4 were localized in the thoracolumbar segment
or lumbar. Only 1 case was localized in the cauda equina.
Detailed neuroradiology was available for 9 cases. Their
magnetic resonance imaging scans showed mostly well-
demarcated lesions, displaying some cystic features and
presenting with variable, often strong contrast enhancement
(Fig. 1). According to the clinical information available, 1
patient was affected by neurofibromatosis type 1 (NF-1), the
others did not show clinical features of a tumor predispo-
sition syndrome. For 9 pediatric patients, detailed FU data
were available (mean FU, 2 years 10 months; FU range, 3
months to 5 years 10 months). Of the 9 patients, 7 did not
show progression of the tumor residue, but 2 patients
received radiotherapy after appearance of neurologic symp-
toms. One patient had a second surgical intervention a few
months after the first resection due to clinical evidence of
tumor progression without further relapse. One patient with
GG of the cauda equina was previously diagnosed with a
pleomorphic xanthoastrocytoma in the posterior fossa, for
which he received radiotherapy and chemotherapy upon
progression. The clinical data are briefly summarized in
the Table.
3.2. Histopathologic features
The histologic specimens consisted of small biopsies (18
cases) or larger tumor resections (7 cases). All GGs (World
Fig. 1 Neuroradiological features of spinal gangliogliomas described in this series. A, A T1 hyperintense tumor at C4 level appeared well
demarcated from surrounding CNS tissue (case 7). B, A contrast-enhancing tumor located at T12-L1 (case 11) shows partially cystic features.
C, The magnetic resonance imaging scans display a partially cystic, partly solid, and contrast-enhancing intramedullary ganglioglioma at T12
level (case 6). The lesion is T1 hyperintense and contrast-enhancing with numerous cysts located centrally.
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characterized by low to moderate cellularity. The astrocytic
tumor component showed variable cytology, mainly piloidTable Clinical features of spinal gangliogliomas included in
this study
Case Age
(y)
Sex Site Diagnosis BRAFV600E
status
1 17 M C4-T1 AGG (WHO III) NA a
2 9 M MO-C4-6 GG (WHO I) Mut
3 3 F C3-5 GG (WHO I) WT
4 13 M MO-C2 GG (WHO I) WT
5 4 M T11-L1 GG (WHO I) WT
6 14 F T10-12 AGG (WHO III) WT
7 13 F C4 GG (WHO I) WT
8 8 M C7-T2 GG (WHO I) Mut
9 49 M T6-7 GG (WHO I) NA
10 63 M C3-C5 AGG (WHO III) WT
11 68 F T12-L1 GG (WHO I) WT
12 6 M L4-5 GG (WHO I) NA
13 9 F T10-L1 GG (WHO I) WT b
14 6 F C5-T4-5 GG (WHO I) WT b
15 3 F C6-7, T8-9 GG (WHO I) WT
16 15 M C5-T1 GG (WHO I) WT
17 13 M T10-L2 AGG (WHO III) WT
18 31 M T6-9 GG (WHO I) WT
19 16 M T3-7 GG (WHO I) WT
20 17 F C2-4 GG (WHO I) WT
21 15 F T5-6 GG (WHO I) WT
22 36 F C GG (WHO I) NA
23 20 M C2-5 GG (WHO I) NA
24 1 M C1-T7 GG (WHO I) WT
25 72 M NA GG (WHO I) NA
Abbreviations: M, male; F, female; C, cervical; T, thoracic; L, lumbar;
MO,medulla oblongata;AGG, anaplastic ganglioglioma;GG,ganglioglioma;
WT, wild type; Mut, mutated; NA, not available.
a Patient affected by NF-1.
b Presence of extra copy of KIAA1549 and BRAF genes suggestive
of KIAA1549-BRAF fusion.or microcystic (Fig. 2A). In 2 cases (9%, 2/21), oligo-like
features were present. We found no cases with an
unequivocally biphasic architecture. The glial component
was commonly glial fibrillary acidic protein and variably
MAP2C positive. Eosinophilic granular bodies (EGBs) were
found in 14 cases (66%, 14/21). In 7 cases (33%, 7/21),
Rosenthal fibers were seen. In 3 cases (14%, 3/21), the tumor
presented with abundant hyalinized vessels (Fig. 2B).
Calcifications were seen in 3 GGs (14%, 3/21 cases).
Lymphocytic inflammatory infiltrates were identified in 6
GGs (28%, 6/21). Nine cases (42%, 9/21) displayed an
abundant neuronal component with dysmorphic ganglion
cells (DGCs) (Fig. 2C). In the remaining GGs (WHO grade
I), the DGCs were still easily identifiable also in the
hematoxylin and eosin–stained slide. In only 1 case, this
component was limited to a few cells. The morphology of
dysplastic ganglion cells varied greatly. Most cells displayed
irregular-shaped nuclei and variable, occasionally very large,
plump cytoplasms (Fig. 2D) also with aggregated Nissl
substance. In the large majority of GGs, single or small
clusters of DGC appeared scattered within the tumor tissue.
In 2 cases, large nodules of DGC were observed. Binucleated
neurons were identified in 15 of 21 cases (Fig. 2D). In 1 case,
DGC presented cytoplasmic vacuolizations. In only 1 case,
the neuronal component showed discrete neurocytic cytol-
ogy along with large dysplastic ganglion cells. DGC showed
mainly perisomatic and/or cytoplasmic positivity for synap-
tophysin (Fig. 2E), although the perisomatic pattern
appeared to be more common. Cytoplasmic expression of
chromogranin A was seen in 17 cases (95%, 17/18)
(Fig. 2G). In 15 GGs (71%, 15/21), MAP2C antibody
stained significantly only the neuronal component (Fig. 2F).
In a few cases (26%, 4/15), an abnormal cytoplasmic
accumulation of phosphorylated neurofilaments was seen in
DGC. Mitotic figures were very rare in GG, and the
proliferation index varied between 1% and 4%. Four cases in
our series were compatible with the diagnosis of anaplastic
ganglioglioma (AGG) (WHO grade III). These tumors
Fig. 2 Histopathologic and immunohistochemical features of spinal gangliogliomas included in this study. A, The tumors display mostly a
glial “touch” with a predominant astrocytic component often with piloid cytology (case 6). B, Unusual angiomatous features and calcifications
can be identified in a minority of cases (case 9). C, Occasionally, the tumor may show dense inflammatory infiltrates (case 22). C, Dysplastic
ganglion cells (DGCs) can be easily observed in all cases, scattered within the tumor tissue (case 22) or arranged in small clusters. D, The DGC
appears bizarre, irregularly shaped, occasionally binucleated (case 15), rarely vacuolated. The DGCs express synaptophysin (E), MAP2C (F)
(case 22), and chromogranin (G) (case 5). A cytoplasmic or perisomatic staining pattern can be seen. H, In approximately 60% of cases, a
variable number of CD34-positive “satellite cells” can be detected (case 4).
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(Fig. 3A and B). They also displayed increased cellular
pleomorphism and presence of mitoses (Fig. 3B, D). EGBswere found in 3 cases. Necrosis could be identified in 1 case.
In all AGGs, the DGCs were clearly visible with neuronal
cells mostly intermingled with the glial component (Fig. 3C,
Fig. 3 Histopathologic and immunohistochemical features of spinal anaplastic gangliogliomas included in this study. Anaplastic
gangliogliomas show increased cellularity (A and B), also reminiscent of high-grade glioma (B), note the vascular proliferations (case 1). C,
Besides an anaplastic glial component, DGCs are seen (arrow, binucleated DGC) (case 17). D, The mitotic count and proliferation activity in
anaplastic ganglioglioma appear clearly increased. DGCs express synaptophysin (E) and, occasionally, neurofilaments (F) (case 17).
111Pathology and genetics of spinal gangliogliomasE-F). Binucleated DGCs were identified in 3 of 4 cases and
expressed chromogranin A as well as synaptophysin (Fig. 3E).
Notably, a nuclear positivity for mutant H3.3K27M protein
and negativity for trimethylated H3.3 was detected in 2 AGGs
(2/3 cases investigated, cases 10 and 17).3.3. BRAFV600E and KIAA1549-BRAF fusion
status analysis
BRAFV600E status was investigated in 19 cases (19/25,
76%) using immunohistochemistry (6 cases) or using a
112 M. Gessi et al.pyrosequencing-based assay (13 cases). Notably, we identified
only 2 tumors (2/19; 11%) in our series harboring aBRAFV600E.
These tumors affected a 9-year-old patient with a lesion
extending from the medulla oblongata to the C6 level and an
8-year-old boy with a tumor from C7 to T2, respectively.
In 2 cases (13 and 14), extra copies of KIAA1549
containing exons 11 and 4 as well as exons 17 and 14 of
BRAF were observed and were highly indicative for the
presence of a KIAA1549-BRAF fusion. Three cases did not
show any alteration. That suggests the absence of fusions.
Four displayed inconclusive results. One case revealed gain
of the whole chromosome 7; in another case, an isolated gain
of the whole BRAF gene was detected.4. Discussion
GGs occurring in the spinal cord are extremely rare [6]. In
accordance with the available data from the literature, our
results confirm that spinal GGs may affect a broad spectrum of
age but seem to have a slight predilection for children,
adolescents, or young adults [2,4]. Infants or small children
appear to be rarely affected. With regard to localization, spinal
GGs arise preferentially in the cervical and thoracic spinal cord,
whereas they seem to be rather uncommon in the lumbar
segment as well as in the cauda equina [2-4]. Frequently, these
tumors involve multiple spinal segments including the
craniospinal junction and the medulla oblongata. From a
clinical point of view, spinal GGs are characterized by an
indolent biologic behavior. According to our limited data,
patients with spinal GG seem to have stable disease after
surgical intervention or are stabilized by further intervention or
radiotherapy upon progression. However, given the small
number of patients, we cannot definitively assess the
effectiveness of these strategies. The use of chemotherapy has
been mainly used for AGGs, which usually show more
aggressive clinical behavior [2,4,9]. Unfortunately, we had no
FU data regarding the patients withAGG included in this study.
Histologically, spinal GGs are largely similar to their
hemispheric counterparts. Our analysis identified, however,
some differences, such as the absence of significant
lymphocytic infiltrates and the variable presence of
CD34-positive “satellite” cells, frequently encountered in
epilepsy-associated GG. Although the glial cell component
could be easily detected, the correct identification of the
DGC component of a spinal GG could be challenging. In
fact, preexisting normal neurons in spinal cord nuclei could
be easily misinterpreted as DGC. In our experience, the
presence of bizarre cytology and binucleation, together with
an inhomogeneous chromogranin and synaptophysin posi-
tivity with a perisomatic or cytoplasmic staining pattern,
strongly supports the diagnosis of GG, although this staining
pattern has been also described in normal neurons in the
spinal cord [10,11]. Their limited number may also cause
diagnostic difficulties. In fact, the frequency of these cellsmay vary within the tumor tissue ranging from many (as
observed in most cases of our series) to very few. If the
DGCs are rare, the differential diagnosis with a pilocytic
astrocytoma, which to some extent may overrun normal
tissue and entrap normal neurons [1], can be difficult or
impossible. Notably, in a recent study [12], posterior fossa
and spinal GG (7 and 4 cases of the 27 cases reported,
respectively) with limited number of DGC have been defined
as “pilocytic astrocytoma with gangliocytic component,” due
to their great similarities with pilocytic astrocytomas. This
group of tumors presented a biphasic pattern of growth and
frequent Rosenthal fibers besides a focal intratumoral
ganglion cell component. From a genetic point of view, all
these cases harbored, like pilocytic astrocytomas,
KIAA1549-BRAF fusions. Although the confusion between
pilocytic astrocytoma and GG (both are grade I tumors
according to the 2007 WHO classification) [1] may have no
significant implications in the management of these patients, the
distinction between GG and diffuse astrocytoma (WHO grade
II) infiltrating the surrounding nerve tissue may be noteworthy.
The neuroimaging could be helpful in this distinction.
Anaplastic GGs are rare in the spinal cord, and only a few
cases have been previously described [9]. The anaplastic
features were detectable exclusively in the glial component
and included presence of mitoses, increased proliferative
activity, necrosis, and/or vascular proliferations. In these cases,
the differential diagnosis with high-grade astrocytic tumors may
be very difficult. The clinical history of the patient (ie,
information about previously resected spinal low-grade GG)
and some histologic features, such as presence of EGBs and
binucleated synaptophysin-positive ganglion cells within a
high-grade tumor, may point toward the presence of AGG. In
our series, besides one patient with clinical history of
previously resected spinal GG (case 1), the other lesion
showed presence of EGBs and presence of binucleated
synaptophysin-positive ganglion cells. In particular, binuclea-
tion could be very helpful to identify anaplastic GGs being, in
our opinion, a very unusual feature to be found in normal
neurons entrapped within the tumor.
Notably, 2 AGGs showed positivity for antibody against
mutated H3.3K27M protein, indicating the presence of an
underlying mutation, H3F3AK27M, which is typically found
in midline high-grade gliomas affecting children and adults
[13]. As already indicated by the evidence of TP53
mutations, CDKN2A deletions in AGG [1], it cannot be
excluded that such cases may share to some extent other
molecular features with high-grade gliomas, especially in
midline lesions. Glioneuronal tumors with malignant
features harboring both H3F3AK27M and BRAFV600E muta-
tion have been recently described [14]. Whether patients with
spinal AGG have different clinical outcome in comparison
with high-grade gliomas has to be determined.
In case of a spinal tumor with poorly differentiated or
clearly malignant neuronal component, the presence of a
neuroblastoma or ganglioneuroblastoma must be considered
in the differential diagnosis.
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their supratentorial counterparts, they apparently display
different molecular features. According to our data, BRAF
mutations seem to be rare in spinal GG. Notably, we found only
2BRAFV600Emutated cases. In the study of Gupta et al [12] all 4
spinal GGs, classified as “pilocytic astrocytoma with gang-
liocytic component,” showed a KIAA-BRAF fusion, but no
BRAFV600E mutations. Although the analysis was limited to 12
cases of our series, we also identified 2 tumors harboring an
extra copy of KIAA1549 and BRAF, highly indicative for the
presence of a KIAA1549-BRAF fusion.
BRAF, a member of the serine/threonine kinase protein
family, is as an immediate downstream effector of RAS in the
RAS/RAF/MEK/ERK signaling cascade, a signal transduction
pathway that modulates various intracellular processes, includ-
ing cell proliferation and survival [15]. The most frequent
mutation is the BRAFV600E which leads to a significant increase
of BRAF kinase activity. BRAFV600E mutations have been
found in pilocytic astrocytomas (15%-20% of cases), WHO
grade II to IV diffuse astrocytomas (5% of cases), and
pleomorphic xanthoastrocytomas (in 60%-70% of cases) as
well as in GGs [16-18]. The incidence of BRAF mutations in
supratentorial GGs varies from study to study [16,17] ranging
from 15% to 60%. In brainstem GG, the incidence of
BRAFV600E ranges from 40% to 50% of cases [12,19]. The
presence of BRAFV600E mutation seems to be associated with
shorter progression-free survival in pediatric patients [19,20]
with GG.
Spinal GGs seem to be rare in patients affected by NF-1, and
only a few cases have been reported [21,22]. In our series, we
reported 1 additional case of an AGG arising in the
cervical-thoracic region of a young NF-1 patient. Spinal GGs
are also exceedingly rare in patients with neurofibromatosis type
2, and only 1 neurofibromatosis type 2–associated GG has been
described to date [23].
In conclusion, although spinal GGs display histologic and
clinical features similar to their supratentorial counterparts, they
show a relatively low frequency of BRAFV600E mutations, an
alteration otherwise common in hemispheric and brain stemGGs.References
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